cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28075466.v2
title: Supplementary Material for: Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis

description: Introduction: Emerging evidences have underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic.
Methods: The database of PubMed, Embase, Web of Science, and Cochrane Library were comprehensively searched in our study until May 29th, 2024. Only randomized controlled trials were included to estimate the value of biologics on asthmatic children and adolescents. Data extraction and risk of bias assessment were independently performed by two researchers. Outcomes were analyzed by a fixed effects model, and the surface under the cumulative ranking (SUCRA) scores were calculated to determine the likelihood of each biologic being the most effective intervention.
Results: 2,672 patients were included for comparing four different biologics (dupilumab, omalizumab, lebrikizumab, and mepolizumab) with a placebo. Dupilumab has been demonstrated the highest efficacy in reducing asthmatic exacerbations, improving lung function and patients’ quality of life, with the SUCRA values of 0.956, 0.999 and 0.897, respectively. Omalizumab showed the best safety potential by reducing the risk of adverse and severe events, with the SUCRA values of 0.876 and 0.930.
Conclusions: In this NMA, focusing on biologics that target type 2 inflammation in childhood and adolescent asthma, that four biologics demonstrated a favorable safety profile. Notably, dupilumab emerged as the most effective, while omalizumab was identified as the safest therapy. Further studies must be conducted in order to confirm these findings.
DOI: 10.6084/m9.figshare.28075466.v3
title: Supplementary Material for: Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis

description: Introduction: Emerging evidences have underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic.
Methods: The database of PubMed, Embase, Web of Science, and Cochrane Library were comprehensively searched in our study until May 29th, 2024. Only randomized controlled trials were included to estimate the value of biologics on asthmatic children and adolescents. Data extraction and risk of bias assessment were independently performed by two researchers. Outcomes were analyzed by a fixed effects model, and the surface under the cumulative ranking (SUCRA) scores were calculated to determine the likelihood of each biologic being the most effective intervention.
Results: 2,672 patients were included for comparing four different biologics (dupilumab, omalizumab, lebrikizumab, and mepolizumab) with a placebo. Dupilumab has been demonstrated the highest efficacy in reducing asthmatic exacerbations, improving lung function and patients’ quality of life, with the SUCRA values of 0.956, 0.999 and 0.897, respectively. Omalizumab showed the best safety potential by reducing the risk of adverse and severe events, with the SUCRA values of 0.876 and 0.930.
Conclusions: In this NMA, focusing on biologics that target type 2 inflammation in childhood and adolescent asthma, that four biologics demonstrated a favorable safety profile. Notably, dupilumab emerged as the most effective, while omalizumab was identified as the safest therapy. Further studies must be conducted in order to confirm these findings.
DOI: 10.6084/m9.figshare.28075466.v4
title: Supplementary Material for: Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis

description: Introduction: Emerging evidences have underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic.
Methods: The database of PubMed, Embase, Web of Science, and Cochrane Library were comprehensively searched in our study until May 29th, 2024. Only randomized controlled trials were included to estimate the value of biologics on asthmatic children and adolescents. Data extraction and risk of bias assessment were independently performed by two researchers. Outcomes were analyzed by a fixed effects model, and the surface under the cumulative ranking (SUCRA) scores were calculated to determine the likelihood of each biologic being the most effective intervention.
Results: 2,672 patients were included for comparing four different biologics (dupilumab, omalizumab, lebrikizumab, and mepolizumab) with a placebo. Dupilumab has been demonstrated the highest efficacy in reducing asthmatic exacerbations, improving lung function and patients’ quality of life, with the SUCRA values of 0.956, 0.999 and 0.897, respectively. Omalizumab showed the best safety potential by reducing the risk of adverse and severe events, with the SUCRA values of 0.876 and 0.930.
Conclusions: In this NMA, focusing on biologics that target type 2 inflammation in childhood and adolescent asthma, that four biologics demonstrated a favorable safety profile. Notably, dupilumab emerged as the most effective, while omalizumab was identified as the safest therapy. Further studies must be conducted in order to confirm these findings.
DOI: 10.15468/dl.qp9upe
title: Occurrence Download

description: A dataset containing 3 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Madagascar",
 "TaxonKey is Cheirogaleus grovesi McLain, Lei, Frasier, Taylor, Bailey, Roberts, Nash, Randriamanana, Mittermeier & Louis Jr., 2017"
 ]
}

 The dataset includes 3 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046800-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.28075466
title: Supplementary Material for: Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis

description: Introduction: Emerging evidences have underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic.
Methods: The database of PubMed, Embase, Web of Science, and Cochrane Library were comprehensively searched in our study until May 29th, 2024. Only randomized controlled trials were included to estimate the value of biologics on asthmatic children and adolescents. Data extraction and risk of bias assessment were independently performed by two researchers. Outcomes were analyzed by a fixed effects model, and the surface under the cumulative ranking (SUCRA) scores were calculated to determine the likelihood of each biologic being the most effective intervention.
Results: 2,672 patients were included for comparing four different biologics (dupilumab, omalizumab, lebrikizumab, and mepolizumab) with a placebo. Dupilumab has been demonstrated the highest efficacy in reducing asthmatic exacerbations, improving lung function and patients’ quality of life, with the SUCRA values of 0.956, 0.999 and 0.897, respectively. Omalizumab showed the best safety potential by reducing the risk of adverse and severe events, with the SUCRA values of 0.876 and 0.930.
Conclusions: In this NMA, focusing on biologics that target type 2 inflammation in childhood and adolescent asthma, that four biologics demonstrated a favorable safety profile. Notably, dupilumab emerged as the most effective, while omalizumab was identified as the safest therapy. Further studies must be conducted in order to confirm these findings.
DOI: 10.6084/m9.figshare.28075466.v5
title: Supplementary Material for: Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis

description: Introduction: Emerging evidences have underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic.
Methods: The database of PubMed, Embase, Web of Science, and Cochrane Library were comprehensively searched in our study until May 29th, 2024. Only randomized controlled trials were included to estimate the value of biologics on asthmatic children and adolescents. Data extraction and risk of bias assessment were independently performed by two researchers. Outcomes were analyzed by a fixed effects model, and the surface under the cumulative ranking (SUCRA) scores were calculated to determine the likelihood of each biologic being the most effective intervention.
Results: 2,672 patients were included for comparing four different biologics (dupilumab, omalizumab, lebrikizumab, and mepolizumab) with a placebo. Dupilumab has been demonstrated the highest efficacy in reducing asthmatic exacerbations, improving lung function and patients’ quality of life, with the SUCRA values of 0.956, 0.999 and 0.897, respectively. Omalizumab showed the best safety potential by reducing the risk of adverse and severe events, with the SUCRA values of 0.876 and 0.930.
Conclusions: In this NMA, focusing on biologics that target type 2 inflammation in childhood and adolescent asthma, that four biologics demonstrated a favorable safety profile. Notably, dupilumab emerged as the most effective, while omalizumab was identified as the safest therapy. Further studies must be conducted in order to confirm these findings.
DOI: 10.6084/m9.figshare.28080359.v1
title: Supplementary Material for: “The Road Less Traveled” - Ciliary Sulcus Implantation of the Preserflo MicroShunt

description: Introduction Herein, we report on the option and clinical advantage of the Preserflo MicroShunt insertion into the posterior chamber ciliary sulcus in a patient with advanced pseudo-exfoliation glaucoma at a high risk of corneal decompensation.
Case presentation We describe a 64-year-old advanced pseudoexfoliation glaucoma patient who despite maximal tolerated medical therapy and two failed glaucoma surgeries, still suffered from uncontrolled intraocular pressure (IOP) of 36mmHg in his left eye. The patient underwent the implantation of the Preserflo MicroShunt. The shunt was placed nasally into an area of unscarred conjunctiva, with the anterior part of the shunt inserted into the ciliary sulcus. Postoperatively, the patient’s IOP dropped to 6 mmHg on the first day and stabilized at 11 mmHg at the 6-month mark. An elevated, posteriorly located bleb was observed, and the patient no longer required additional topical medications. Endothelial cell (EC) count remained stable with no signs of corneal edema. The patient did not experience any serious post-operative complications.
Conclusion Implantation of the Preserflo MicroShunt into the ciliary sulcus appears to be a viable option for patients at high risk of corneal decompensation, hence, offering effective IOP control while minimizing EC loss. Further studies with larger patient groups are warranted to better evaluate the safety and efficacy of this technique.
DOI: 10.15468/dl.tq23a4
title: Occurrence Download

description: A dataset containing 225 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Madagascar",
 "TaxonKey is Cheirogaleus major É.Geoffroy Saint-Hilaire, 1812"
 ]
}

 The dataset includes 225 records from 23 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046801-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.62rpmn
title: Occurrence Download

description: A dataset containing 193 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Ganoderma gibbosum (Blume & T.Nees) Pat., 1897"
 ]
}

 The dataset includes 193 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046802-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rvkcrt
title: Occurrence Download

description: A dataset containing 960930 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Zimbabwe",
 "OccurrenceStatus is Present",
 "Year 2012-2023"
 ]
}

 The dataset includes 960930 records from 72 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046785-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.v9be24
title: Occurrence Download

description: A dataset containing 228 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Madagascar",
 "TaxonKey is Cheirogaleus medius É.Geoffroy Saint-Hilaire, 1812"
 ]
}

 The dataset includes 228 records from 17 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046803-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ge8dcy
title: Occurrence Download

description: A dataset containing 225260 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Cameroon",
 "OccurrenceStatus is Present",
 "Year 2011-2023"
 ]
}

 The dataset includes 225260 records from 164 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046788-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.14541976
title: HAF 2024 - Automatisk genkendelse af smerte hos heste - Horse pain/no pain - cropped images

description: 605 frames from 22 videos of 11 horses, judged by a human expert to either show or not show equine pain face.

All images are cropped to center on the horse's face.

Frames with visible human faces have been removed from the original data sæt. 

The file names follow the following format:

cropped_[pain or nopain]_video[video#]_1_[frame#].png
DOI: 10.5281/zenodo.14541977
title: HAF 2024 - Automatisk genkendelse af smerte hos heste - Horse pain/no pain - cropped images

description: 605 frames from 22 videos of 11 horses, judged by a human expert to either show or not show equine pain face.

All images are cropped to center on the horse's face.

Frames with visible human faces have been removed from the original data sæt. 

The file names follow the following format:

cropped_[pain or nopain]_video[video#]_1_[frame#].png
DOI: 10.6084/m9.figshare.28082615
title: Delphi Study of Adherence to Tuberculosis Treatment Questionnaires

description: This research endeavor sought to acquire the perspectives of both experts and patients regarding the attributes associated with adherence to tuberculosis (TB) treatment. A total of 20 specialists in the field of TB and 10 patients diagnosed with pulmonary TB participated in a three-round Delphi study designed to categorize and validate the attributes of the concept in question. The results revealed that adherence to TB treatment pertains to the stage wherein patients with pulmonary TB are capable of adhering to the prescribed treatment recommendations, which encompass behaviors related to medication intake as well as lifestyle modifications, including nutritional care, cessation of smoking, abstaining from alcohol, stress management, enhancement of physical activity, improvement in sleep quality and rest, and engagement in TB-related preventive behaviors. In conclusion, the study's findings contribute to a deeper understanding of the critical significance of adherence to TB treatment. The established consensus priorities underscore that the concept encompasses not merely the act of medication consumption but also highlights the paramount importance of implementing lifestyle changes.
DOI: 10.6084/m9.figshare.28082615.v1
title: Delphi Study of Adherence to Tuberculosis Treatment Questionnaires

description: This research endeavor sought to acquire the perspectives of both experts and patients regarding the attributes associated with adherence to tuberculosis (TB) treatment. A total of 20 specialists in the field of TB and 10 patients diagnosed with pulmonary TB participated in a three-round Delphi study designed to categorize and validate the attributes of the concept in question. The results revealed that adherence to TB treatment pertains to the stage wherein patients with pulmonary TB are capable of adhering to the prescribed treatment recommendations, which encompass behaviors related to medication intake as well as lifestyle modifications, including nutritional care, cessation of smoking, abstaining from alcohol, stress management, enhancement of physical activity, improvement in sleep quality and rest, and engagement in TB-related preventive behaviors. In conclusion, the study's findings contribute to a deeper understanding of the critical significance of adherence to TB treatment. The established consensus priorities underscore that the concept encompasses not merely the act of medication consumption but also highlights the paramount importance of implementing lifestyle changes.
DOI: 10.15468/dl.zudkwc
title: Occurrence Download

description: A dataset containing 6 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Madagascar",
 "TaxonKey is Cheirogaleus shethi Frasier, Lei, McLain, Taylor, Bailey et al., 2016"
 ]
}

 The dataset includes 6 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046804-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.fbbqp5
title: Occurrence Download

description: A dataset containing 263 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Abundisporus fuscopurpureus (Pers.) Ryvarden"
 ]
}

 The dataset includes 263 records from 30 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046805-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.nxj22z
title: Occurrence Download

description: A dataset containing 432 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Material sample",
 "TaxonKey is Medicago archiducis-nicolai Širj."
 ]
}

 The dataset includes 432 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046806-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.28082597
title: U-Pb age database of detrital zircons from the Sandy Land in Northeast China

description: This dataset comprises a U-Pb age database of detrital zircons from four major sandy lands in Northeast China(i.e., Otindaga Sandy Land, Horqin Sandy Land, Songnen Sandy Land, and Hulunbuir Sandy Land). The database includes a total of 2682 analyzable zircon ages.
DOI: 10.6084/m9.figshare.28082597.v1
title: U-Pb age database of detrital zircons from the Sandy Land in Northeast China

description: This dataset comprises a U-Pb age database of detrital zircons from four major sandy lands in Northeast China(i.e., Otindaga Sandy Land, Horqin Sandy Land, Songnen Sandy Land, and Hulunbuir Sandy Land). The database includes a total of 2682 analyzable zircon ages.
DOI: 10.5281/zenodo.14547930
title: Genetic differences in voracity influence biocontrol efficacy and fruit damage by Dicyphus hesperus in greenhouses
DOI: 10.5281/zenodo.14547931
title: Genetic differences in voracity influence biocontrol efficacy and fruit damage by Dicyphus hesperus in greenhouses
DOI: 10.15468/dl.knmwss
title: Occurrence Download

description: A dataset containing 15 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Heteromys teleus Anderson & Jarrín-V., 2002"
 ]
}

 The dataset includes 15 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046808-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.jdrjdd
title: Occurrence Download

description: A dataset containing 3518249 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Venezuela (Bolivarian Republic of)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Chordata"
 ]
}

 The dataset includes 3518249 records from 307 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046807-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.28079372
title: DataPollen

description: Exploring Pollen Traits and Their Significance in the Conservation and Genetic Preservation of Moroccan Cannabis Cultivars
DOI: 10.15468/dl.enetpx
title: Occurrence Download

description: A dataset containing 55 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "OccurrenceStatus is Present",
 "TaxonKey is Streltzoviella insularis (Staudinger, 1892)"
 ]
}

 The dataset includes 55 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046811-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.pgfe98
title: Occurrence Download

description: A dataset containing 23192 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is iNaturalist Research-grade Observations",
 "Geometry POLYGON((-80.27801 43.33639,-80.00468 43.33639,-80.00468 43.43891,-80.27801 43.43891,-80.27801 43.33639))",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 23192 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046812-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.8cqk7g
title: Occurrence Download

description: A dataset containing 1315 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is eButterfly Surveys",
 "Geometry POLYGON((-80.27801 43.33639,-80.00468 43.33639,-80.00468 43.43891,-80.27801 43.43891,-80.27801 43.33639))",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 1315 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0046813-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.